Claims for harm from Allergan implants in Ohio

Ohio plaintiffs may join MDL 2921 in the District of New Jersey (Judge Brian R. Martinotti) or file in Ohio state court. Ohio has no statewide BIOCELL coordinated proceeding. Federal filings from Ohio originate in the Northern District of Ohio (Cleveland or Akron Divisions) or Southern District of Ohio (Columbus or Cincinnati Divisions) before transfer to D.N.J. under JPML procedures. Ohio is a mid-tier plaintiff state in MDL 2921 by volume.

Ohio applies a two-year statute of limitations for bodily injury under Ohio Rev. Code § 2305.10(A). Ohio recognizes the discovery rule: the cause of action accrues when the plaintiff knew or should have known of the injury and its probable cause. For BIA-ALCL plaintiffs, Ohio courts apply this from the diagnosis date. Ohio also has a products liability statute of repose — ten years from delivery of the product to the first purchaser (ORC § 2305.10(C)) — which is relevant for early-era BIOCELL placements; consult applicable tolling provisions.

Cuyahoga County Court of Common Pleas (Cleveland) is the largest Ohio mass tort venue and has prior experience with pharmaceutical and medical device cases. Franklin County Common Pleas (Columbus) and Hamilton County Common Pleas (Cincinnati) are the other primary venues. In federal court, Northern District of Ohio Chief Judge J. Philip Calabrese (Cleveland) and Southern District of Ohio judges in Columbus handle complex product liability matters. Ohio follows Daubert for expert admissibility under Ohio Evid. R. 702.

Ohio BIOCELL exposure is concentrated in the Cleveland–Akron metro (Cuyahoga, Summit, Lorain counties), Columbus (Franklin County), Cincinnati (Hamilton, Butler, Warren counties), and Dayton. Academic plastic surgery programs at Cleveland Clinic, University Hospitals Cleveland, Ohio State Wexner Medical Center, and Cincinnati Children's Hospital Medical Center affiliates contributed to implant volume during the recall era. Ohio's cosmetic surgery market is driven by a combination of urban centers and mid-sized metro areas with active plastic surgery practices.